Yet, in a multicenter, phase II trial of 17 c-KIT-mutant or -amplified mucosal melanoma patients, Hodi and colleagues reported an ORR of 64% with imatinib among those with c-KIT mutations but not amplification [81]. The gene discussed is KIT; the disease is melanoma.